A humanized antibody inhibitor for cathepsin L

Area of Science:

• Biochemistry
• Immunology
• Drug Discovery

Background:

• Cathepsin L (CTSL) is a cysteine protease implicated in numerous physiological and pathological processes.
• Existing CTSL inhibitors lack specificity and optimal pharmacological profiles, necessitating the development of novel agents.
• Selective inhibition of CTSL is crucial for therapeutic interventions and research.

Purpose of the Study:

• To engineer a humanized antibody inhibitor targeting Cathepsin L (CTSL).
• To establish a novel platform for rapidly generating potent and specific antibody-based protease inhibitors.

Main Methods:

• Genetically fusing the inhibitory propeptide of procathepsin L to the N-terminus of a humanized antibody's light chain.
• Assessing the stability, expression, inhibitory activity, and specificity of the resulting antibody fusion protein.

Main Results:

• The generated antibody fusion was stably expressed.
• The antibody fusion demonstrated highly potent and specific inhibition of CTSL activity.
• This method provides a new strategy for developing CTSL inhibitors.

Conclusions:

• A novel humanized antibody inhibitor of CTSL was successfully generated using a genetic fusion approach.
• This strategy offers a rapid and effective method for creating specific antibody inhibitors against CTSL.
• The approach holds potential for developing inhibitors targeting other cathepsin proteases for research and therapeutic applications.